Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy

Background. Due to the high prevalence of multiple sclerosis (MS) among women of reproductive age, special attention is paid to the management of pregnancy in them. The problem concerning the health of infants born to mothers with MS receiving disease-modifying therapy has not yet been addressed. It is necessary to identify the timing of cessation of drugs changing the course of MS, as well as to find the possibility of mitigating exacerbations during pregnancy using corticosteroid therapy.Objective: to analyze the effects of causal therapy for MS on the health of newborns.Materials and methods. This study included 154 women with MS residing in Moscow region and receiving disease-modifying therapy. We evaluated the course of pregnancy, delivery, and the condition of infants born to these mothers.Results and conclusions. Our findings are consistent with the earlier published data in the general cohort of pregnant women and allowed us to conclude that the presence of MS and history of immunomodulatory therapy do not significantly affect the outcome of pregnancy. The incidence and severity of disorders in infants born to MS mothers did not significantly differ from those in the general population. Prolongation of therapy with drugs that change the course of MS up to pregnancy is most appropriate, since it stabilizes the condition of women in the perinatal period, without causing significant harm to the health of newborns. Immunosuppressive therapy increases the risk of various disorders in infants (such as multiple malformations, low birth weight, prematurity). If a woman develops an exacerbation of MS during pregnancy, it is possible to prescribe a short course of pulse therapy with methylprednisolone.

Download Full-text

Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy

International Journal of MS Care ◽

10.7224/1537-2073.2016-056 ◽

2016 ◽

Vol 18 (6) ◽

pp. 305-310 ◽

Cited By ~ 18

Author(s):

Matthew M. Mirsky ◽

Ruth Ann Marrie ◽

Alexander Rae-Grant

Keyword(s):

Multiple Sclerosis ◽

Drug Use ◽

Performance Management ◽

Large Scale ◽

Antidepressant Drug ◽

Dimethyl Fumarate ◽

Disease Modifying Therapy ◽

Multiple Sclerosis Disease ◽

Disease Modifying ◽

The Relationship

Background: The Explorys Enterprise Performance Management (EPM) database contains de-identified clinical data for 50 million patients. Multiple sclerosis (MS) disease-modifying therapies (DMTs), specifically interferon beta (IFNβ) treatments, may potentiate depression. Conflicting data have emerged, and a large-scale claims-based study by Patten et al. did not support such an association. This study compares the results of Patten et al. with those using the EPM database. Methods: “Power searches” were built to test the relationship between antidepressant drug use and DMT in the MS population. Searches were built to produce a cohort of individuals diagnosed as having MS in the past 3 years taking a specific DMT who were then given any antidepressant drug. The antidepressant drug therapy prevalence was tested in the MS population on the following DMTs: IFNβ-1a, IFNβ-1b, combined IFNβ, glatiramer acetate, natalizumab, fingolimod, and dimethyl fumarate. Results: In patients with MS, the rate of antidepressant drug use in those receiving DMTs was 40.60% to 44.57%. The rate of antidepressant drug use for combined IFNβ DMTs was 41.61% (males: 31.25%–39.62%; females: 43.10%–47.33%). Antidepressant drug use peaked in the group aged 45 to 54 years for five of six DMTs. Conclusions: We found no association between IFNβ treatment and antidepressant drug use in the MS population compared with other DMTs. The EPM database has been validated against the Patten et al. data for future use in the MS population.

Download Full-text

Adverse Drug Reactions of Multiple Sclerosis Disease-Modifying Drugs

Basic and Clinical Neuroscience Journal ◽

10.32598/bcn.2021.2848.2 ◽

2021 ◽

pp. 1-10

Author(s):

Maryam Salehbayat ◽

◽

Roya Abolfazli ◽

Niayesh Mohebbi ◽

Seyed Mehrdad Savar ◽

...

Keyword(s):

Multiple Sclerosis ◽

Adverse Drug Reactions ◽

High Frequency ◽

Cross Sectional Study ◽

Drug Reactions ◽

Cross Sectional ◽

Disease Modifying Drugs ◽

Disease Modifying Therapy ◽

Multiple Sclerosis Disease ◽

Disease Modifying

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. We aimed to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Material and Methods: ADRs of all outpatients who had been visiting a neurologist and had been receiving at least one disease-modifying therapy (DMT) for MS during the last three months were investigated. Results: A total number of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious. Discussion: The high frequency of adverse drug reactions in this study shows a strong need for planning a strategy to increase patients' adherence to treatment.

Download Full-text